ISCHEMIA Trial and the Significance of MI
During the past decade, the treatment of choice for chronic coronary syndromes (CCS) has been a contentious issue. Whether revascularisation, either percutaneous or surgical, or optimal medical therapy, offers better prognosis in terms of mortality, MI, and symptom relief, has yet to be confirmed. T...
Saved in:
Main Authors: | Eduardo A Arias, Félix Damas-de los Santos, Heriberto Ontiveros-Mercado |
---|---|
Format: | article |
Language: | EN |
Published: |
Radcliffe Medical Media
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/27f8c08c55f44a4e92f157da82c56f8d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed
by: Joel P Giblett, et al.
Published: (2020) -
Clinical significance of hsCRP level in acute coronary syndrome
by: V.K. Katyal, et al.
Published: (2021) -
Reprising an old friend – The Athens QRS score as a predictor of coronary artery disease in patients with intermediate treadmill test during ischemia evaluation
by: Prayaag Kini, et al.
Published: (2021) -
A study of immediate and long-term results of significant tricuspiud regurgitation after percutaneous mitral balloon valvotomy
by: Remala Archana, et al.
Published: (2021) -
Clinical profile of patients with qRBBB MI at tertiary care centre
by: Achal Sharma, et al.
Published: (2021)